Back To: Home



CLICK HERE FOR WHAT'S NEW IN:
 
Our 2020 Media Kit is now available
Your gateway to the latest oncology news, trends and resources
 
Inside this issue:
January 2020
Samumed publishes unique mechanism of action for SM08502...
by Mel J. Yeates
January 2020
Oramed's oral insulin candidate shows efficacy in Phase 2b diabetes trial...
by Kelsey Kaustinen
January 2020
Mission and AbbVie deal reaches milestone as partnership continues...
by Kelsey Kaustinen
January 2020
Researchers move beyond cut-and-paste to address genetic disorders...
by Randall C Willis
 
FEATURED CONTENT
Patent Docs: More in patent-ineligibility from the Federal Circuit
In his latest column, Kevin Noonan discusses how the Federal Circuit continues to expand the scope of patent-ineligible invention in its recent iNo Therapeutics LLC v. Praxair Distribution Inc. decision, relying on Justice Breyer's exhortation, in his Mayo Collaborative Serv. Inc. v. Prometheus Laboratories opinion. To read it, click here.

Focus Feature on Cancer Research News
Oncology: Stem to Stern
A look at gastroesophageal, gastric and colorectal cancer progress, as well as other recent news of oncology research breakthroughs. To read it, click here.

Focus Feature on CRISPR Gene Editing
What’s new with CRISPR?
A roundup of recent news and breakthroughs with the gene-editing technology. To read it, click here.

Special Report on Cell Biology: Making bioprogress
Expanding bioprocess analytics to ensure quality. To read it, click here.

Editor's Focus:
January 2020
Collaboration between drug discovery groups from different sites, organizations and companies has become much more common, and distributing research can have profound advantages even as managing the process poses unique challenges.. [ more ]
by Julia M. Adam of Mironid et al

January 2020
Science is elusive and ever shifting, refusing to come into focus, and that is both its curse and its blessing.. [ more ]
by Randall C Willis

January 2020
Of all the areas where 'just because you can doesn't mean you should' ought to be a leading tenet, genomics is at the top of the list. The promise of gene editing must be partnered with caution regarding the ways it could be mishandled; we need to decide now which lines shouldn't be crossed, rather than backtracking after someone steps over them... [ more ]
by Jeffrey Bouley

 
CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by Offenberger & White.